The first step of this study comprised the evaluation of mRNA levels of both BRD4 variants in total bone marrow cells from healthy donors (n = 24), MDS (n = 58), and AML (n = 50) patients. This evidence concerns the gene BRD4 and myelodysplastic syndrome.